{"id":17185,"date":"2023-06-02T08:54:16","date_gmt":"2023-06-02T12:54:16","guid":{"rendered":"https:\/\/ifintechworld.com\/markets\/should-you-pick-stryker-stock-over-bax-for-better-returns\/"},"modified":"2023-06-02T08:54:17","modified_gmt":"2023-06-02T12:54:17","slug":"should-you-pick-stryker-stock-over-bax-for-better-returns","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=17185","title":{"rendered":"Should You Pick Stryker Stock Over BAX For Better Returns?"},"content":{"rendered":"<div>\n<p>We believe <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/SYK\/\">Stryker stock<\/strong> (NYSE: SYK) is a better pick in the Medical Devices industry than <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BAX\/\">Baxter stock<\/strong> (NYSE: BAX), given its better prospects. Although SYK trades at a superior valuation of <strong>5.5<\/strong>x trailing revenues vs. <strong>1.4x<\/strong> for BAX, this gap in valuation makes sense to a large extent, given the former\u2019s better profitability and financial position, as discussed below.<\/p>\n<p>Looking at stock returns, SYK has fared much better with 13% returns this year vs. -20% returns for BAX and 9% gains for the broader S&amp;P500 index. There is more to the comparison, and in the sections below, we discuss why we believe that SYK will offer better returns than BAX in the next three years. We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/SYK\/no-login-required\/Mk1eCz6W\/Stryker-vs-Baxter-With-Return-Forecast-Of-20-Stryker-Is-A-Better-Bet?fromforbesandarticle=trefis230602\">Stryker vs. Baxter<\/strong>: <strong>Which Stock Is A Better Bet?<\/strong> Parts of the analysis are summarized below.<\/p>\n<p><strong>1. Baxter\u2019s Revenue Growth Is Better <\/strong><\/p>\n<ul>\n<li>Baxter\u2019s revenue growth has been slightly better, with a <strong>10.2%<\/strong> average annual growth rate in the last three years, compared to <strong>7.8%<\/strong> for Stryker<fbs-ticker data-name=\"SYK\" data-href=\"https:\/\/www.forbes.com\/companies\/stryker\" data-type=\"stock\"><br \/>\n   SYK<br \/>\n  <\/fbs-ticker>.<\/li>\n<li>Stryker\u2019s revenue growth has been driven by new product launches, such as \u2013 Surgi-Count+ \u2013 a surgical sponge counting system, Insignia Hip Stem, Power-PRO 2 ambulance cot, and Vecta 71\/74 aspiration system, among others. Of late, it has seen a rise in volume for both of its segments \u2013 MedSurg &amp; Neurotechnology and Orthopedics and Spine.<\/li>\n<li>Stryker\u2019s revenue growth has also been buoyed by the acquisition of Wright Medical, a medical device company, in late 2020, and Vocera Communications \u2013 a company focused on communications systems for the healthcare industry \u2013 last year.<\/li>\n<li>Baxter\u2019s sales growth has been led by increased demand for its advanced surgery products. In December 2021, Baxter completed the Hillrom acquisition, which added connected care offerings, including Smart Beds and patient monitoring products, to Baxter\u2019s existing portfolio of the acute, nutritional, renal, hospital, and surgical care products.<\/li>\n<li>However, Baxter\u2019s 2023 guidance of low single-digit sales growth, and earnings falling to $2.92 on a per share and adjusted basis at the mid-point of its guidance, didn\u2019t sit well with the investors. The company\u2019s management cited external macroeconomic factors and supply-chain constraints for the lower guidance.<\/li>\n<li>Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/SYK\/no-login-required\/awifHYEe\/Stryker-SYK-Revenue-Comparison?fromforbesandarticle=trefis230602\">Stryker Revenue Comparison<\/strong> and <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BAX\/no-login-required\/a4tTSc1E\/Baxter-BAX-Revenue-Comparison?fromforbesandarticle=trefis230602\">Baxter Revenue Comparison<\/strong> dashboards provide more insight into the companies\u2019 sales.<\/li>\n<li>Looking forward, Stryker\u2019s revenue is expected to grow faster than Baxter\u2019s over the next three years. The table below summarizes our revenue expectations for the two companies over the next three years. It points to a CAGR of <strong>7.2%<\/strong> for Stryker, compared to a <strong>3.6%<\/strong> CAGR for Baxter, based on Trefis Machine Learning analysis.<\/li>\n<li>Note that we have different methodologies for companies negatively impacted by Covid and those not impacted or positively impacted by Covid while forecasting future revenues. For companies negatively affected by Covid, we consider the quarterly revenue recovery trajectory to predict recovery to the pre-Covid revenue run rate. Beyond the recovery point, we apply the average annual growth observed three years before Covid to simulate a return to normal conditions. For companies registering positive revenue growth during Covid, we consider yearly average growth before Covid with a certain weight to growth during Covid and the last twelve months.<\/li>\n<\/ul>\n<p><fbs-ad position=\"inread\" progressive=\"\" ad-id=\"article-0-inread\" aria-hidden=\"true\" role=\"presentation\"><\/fbs-ad><\/p>\n<p><strong>2. Stryker Is More Profitable<\/strong><\/p>\n<ul>\n<li>Stryker\u2019s operating margin has slid from <strong>18.2%<\/strong> in 2019 to <strong>15.4%<\/strong> in 2022, while Baxter\u2019s operating margin declined from <strong>15.0%<\/strong> to <strong>-15.5%<\/strong> over this period.<\/li>\n<li>Looking at the last twelve-month period, Stryker\u2019s operating margin of <strong>16.5% <\/strong>fares much better than<strong> -15.6% <\/strong>for Baxter.<\/li>\n<li>This sharp decline for Baxter can be attributed to an impairment charge of $3.2 billion on the goodwill related to the Hillrom acquisition.<\/li>\n<li>Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/SYK\/no-login-required\/zBfvvROX\/Stryker-SYK-Operating-Income-Comparison?fromforbesandarticle=trefis230602\">Stryker Operating Income Comparison<\/strong><strong> <\/strong>and <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BAX\/no-login-required\/dkpE4s6c\/Baxter-BAX-Operating-Income-Comparison?fromforbesandarticle=trefis230602\">Baxter Operating Income Comparison<\/strong> dashboards have more details.<\/li>\n<li>Stryker\u2019s free cash flow margin of <strong>15.1%<\/strong> is higher than <strong>9.8%<\/strong> for Baxter.<\/li>\n<li>Looking at financial risk, Stryker fares better with its <strong>12.5%<\/strong> debt as a percentage of equity, lower than <strong>79.8%<\/strong> for Baxter. However, Baxter\u2019s <strong>5.9%<\/strong> cash as a percentage of assets is marginally higher than <strong>4.8% <\/strong>for Stryker, implying that Stryker has a better debt position and Baxter has more cash cushion.<\/li>\n<\/ul>\n<p><strong>3. The Net of It All<\/strong><\/p>\n<ul>\n<li>We see that Stryker is more profitable and has a better debt position. On the other hand, Baxter has seen better revenue growth, is trading at a lower valuation multiple, and has more cash cushion.<\/li>\n<li>Now, looking at prospects, using P\/S as a base, due to high fluctuations in P\/E and P\/EBIT, we believe Stryker is the better choice of the two, despite its higher valuation.<\/li>\n<li>If we compare the current valuation multiples to the historical averages, Baxter fares better, with its stock currently trading at <strong>1.3x<\/strong> trailing revenues vs. the last five-year average of <strong>3.2x. <\/strong>In contrast, Stryker stock trades at <strong>5.4x<\/strong> trailing revenues vs. the last five-year average of <strong>5.9x<\/strong>. Still, we believe Stryker\u2019s better prospects make it a better pick.<\/li>\n<li>Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/SYK\/no-login-required\/G2LeIqEd\/Stryker-SYK-Valuation-Ratios-Comparison?fromforbesandarticle=trefis230602\">Stryker Valuation Ratios Comparison<\/strong> and <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BAX\/no-login-required\/J6w2Sr70\/Baxter-BAX-Valuation-Ratios-Comparison?fromforbesandarticle=trefis230602\">Baxter Valuation Ratios Comparison<\/strong> have more details.<\/li>\n<li>The table below summarizes our revenue and return expectations for Stryker and Baxter over the next three years and points to an expected return of <strong>20%<\/strong> for Stryker over this period vs. an <strong>11%<\/strong> expected return for Baxter, based on Trefis Machine Learning analysis \u2013 <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/SYK\/no-login-required\/Mk1eCz6W\/Stryker-vs-Baxter-With-Return-Forecast-Of-20-Stryker-Is-A-Better-Bet?fromforbesandarticle=trefis230602\">Stryker vs. Baxter<\/strong> \u2013 which also provides more details on how we arrive at these numbers.<\/li>\n<\/ul>\n<p>While SYK may outperform BAX in the next three years, the Covid-19 crisis has created many pricing discontinuities, which can offer attractive trading opportunities. For example, you\u2019ll be surprised at how counter-intuitive the stock valuation is for<strong> <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BAX\/no-login-required\/a1PM3WZ1\/Baxter-vs-Copart-BAX-stock-s-significantly-lower-valuation-vs-CPRT-appears-counterintuitive?fromforbesandarticle=trefis230602\">Baxter vs. Copart<\/strong><strong><br \/>\n  <fbs-ticker data-name=\"CPRT\" data-href=\"https:\/\/www.forbes.com\/companies\/copart\" data-type=\"stock\"><br \/>\n   CPRT<br \/>\n  <\/fbs-ticker>.<\/strong><\/p>\n<p>What if you\u2019re looking for a high-performance portfolio with a low downside instead? Here\u2019s a <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/BPo8U0Xc\/Reinforced-Value-Portfolio-with-439-Return-Since-2016-vs-87-for-S-P-500?fromforbesandarticle=trefis230602\">reinforced value portfolio<\/strong> that has beaten the market consistently while limiting losses during periods of sharp market declines.<\/p>\n<p>Invest with <strong>Trefis <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/dashboards.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/M7MacZNG?fromforbes\">Market Beating Portfolios<\/strong><\/p>\n<p>See all <strong>Trefis <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/dashboards.trefis.com\/data\/price-estimates?fromforbes\">Price Estimates<\/strong><\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.forbes.com\/sites\/greatspeculations\/2023\/06\/02\/should-you-pick-stryker-stock-over-bax-for-better-returns\/\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>We believe Stryker stock (NYSE: SYK) is a better pick in the Medical Devices industry than Baxter stock (NYSE: BAX), given its better prospects. Although SYK trades at a superior valuation of 5.5x trailing revenues vs. 1.4x for BAX, this gap in valuation makes sense to a large extent, given the former\u2019s better profitability and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":17186,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[241],"tags":[83],"class_list":["post-17185","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-markets","tag-featured"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Should You Pick Stryker Stock Over BAX For Better Returns? | iFintechWorld<\/title>\n<meta name=\"description\" content=\"We believe Stryker stock (NYSE: SYK) is a better pick in the Medical Devices industry than Baxter stock (NYSE: BAX), given its better prospects. Although\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=17185\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Should You Pick Stryker Stock Over BAX For Better Returns? | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"We believe Stryker stock (NYSE: SYK) is a better pick in the Medical Devices industry than Baxter stock (NYSE: BAX), given its better prospects. Although\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=17185\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-02T12:54:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-02T12:54:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/06\/1685710456_0x0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=17185#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=17185\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Should You Pick Stryker Stock Over BAX For Better Returns?\",\"datePublished\":\"2023-06-02T12:54:16+00:00\",\"dateModified\":\"2023-06-02T12:54:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=17185\"},\"wordCount\":979,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Markets\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=17185#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=17185\",\"url\":\"https:\/\/ifintechworld.com\/?p=17185\",\"name\":\"Should You Pick Stryker Stock Over BAX For Better Returns? | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-06-02T12:54:16+00:00\",\"dateModified\":\"2023-06-02T12:54:17+00:00\",\"description\":\"We believe Stryker stock (NYSE: SYK) is a better pick in the Medical Devices industry than Baxter stock (NYSE: BAX), given its better prospects. Although\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=17185#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=17185\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=17185#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Should You Pick Stryker Stock Over BAX For Better Returns?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Should You Pick Stryker Stock Over BAX For Better Returns? | iFintechWorld","description":"We believe Stryker stock (NYSE: SYK) is a better pick in the Medical Devices industry than Baxter stock (NYSE: BAX), given its better prospects. Although","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=17185","og_locale":"en_US","og_type":"article","og_title":"Should You Pick Stryker Stock Over BAX For Better Returns? | iFintechWorld","og_description":"We believe Stryker stock (NYSE: SYK) is a better pick in the Medical Devices industry than Baxter stock (NYSE: BAX), given its better prospects. Although","og_url":"https:\/\/ifintechworld.com\/?p=17185","og_site_name":"iFintechWorld","article_published_time":"2023-06-02T12:54:16+00:00","article_modified_time":"2023-06-02T12:54:17+00:00","og_image":[{"width":1200,"height":900,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/06\/1685710456_0x0.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=17185#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=17185"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Should You Pick Stryker Stock Over BAX For Better Returns?","datePublished":"2023-06-02T12:54:16+00:00","dateModified":"2023-06-02T12:54:17+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=17185"},"wordCount":979,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Markets"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=17185#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=17185","url":"https:\/\/ifintechworld.com\/?p=17185","name":"Should You Pick Stryker Stock Over BAX For Better Returns? | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-06-02T12:54:16+00:00","dateModified":"2023-06-02T12:54:17+00:00","description":"We believe Stryker stock (NYSE: SYK) is a better pick in the Medical Devices industry than Baxter stock (NYSE: BAX), given its better prospects. Although","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=17185#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=17185"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=17185#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Should You Pick Stryker Stock Over BAX For Better Returns?"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/17185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17185"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/17185\/revisions"}],"predecessor-version":[{"id":17187,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/17185\/revisions\/17187"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/17186"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}